Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 13/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798920 | 0.91 | POLR1A (0.56) | POLR1AKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL21798919 | 0.91 | POLR1A (0.56) | POLR1AKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL21836065 | 0.88 | POLR1A (0.62) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL29649825 | 0.88 | POLR1A (0.62) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL21836061 | 0.86 | POLR1A (0.58) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL21836090 | 0.85 | POLR1A (0.60) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL29649752 | 0.85 | POLR1A (0.60) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL21836068 | 0.84 | POLR1A (0.61) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL29649787 | 0.84 | POLR1A (0.61) | POLR1AKMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL21993198 | 0.83 | ALDH1A1 (0.72) | POLR1AKMT2AALDH1A1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111247143-B | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2022-07-05 | — | — | CN | claimed |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | ONCOSTELLAE, S.L. (ES) | 2021-06-01 | — | — | US | claimed |
| EP-3632912-B1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE S L (ES) | 2021-03-17 | — | — | EP | claimed |
| CN-111247143-A | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2020-06-05 | — | — | CN | claimed |
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE, S.L. (ES) | 2020-05-14 | — | — | US | claimed |
| EP-3632912-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Oncostellae, S.L. (ES) | 2020-04-08 | — | — | EP | claimed |
| CN-111247143-B | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | ONCOSTELLAE, S.L. (ES) | 2021-06-01 | — | — | US | disclosed |
| EP-3632912-B1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE S L (ES) | 2021-03-17 | — | — | EP | disclosed |
| CN-111247143-A | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE, S.L. (ES) | 2020-05-14 | — | — | US | disclosed |
| EP-3632912-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Oncostellae, S.L. (ES) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K1, MAP4K3 | POLR1A 1623/4885KMT2A 1202/4885ALDH1A1 4264/4885 |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | MAP4K2, MAP4K1, MAP4K3 | POLR1A 1623/4885KMT2A 1202/4885ALDH1A1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.